The relationship between vitamin C and cancer has been studied for over 50 years. From Linus Pauling's early observations to the latest NIH clinical trials, the evidence is complex, nuanced, and increasingly promising — particularly for high-dose intravenous administration.

What does research on vitamin C and cancer study?

Pharmacological intravenous doses of 10 to 100 g, which reach plasma levels 70 to 100 times higher than oral supplements. Those concentrations proved selectively toxic to cancer cells in vitro.

Modern research focuses primarily on pharmacological doses (10–100g IV), which achieve plasma concentrations 70–100x higher than oral supplementation — concentrations shown to be selectively toxic to cancer cells in vitro.

Which mechanisms are under investigation?

Five are described: a pro-oxidant effect generating hydrogen peroxide in tumour tissue at high doses, collagen support for the extracellular matrix, TET-enzyme epigenetic regulation, immune stimulation, and reduced chemotherapy toxicity.

  • Pro-oxidant effect at high doses: generates hydrogen peroxide selectively in tumor tissue
  • Collagen synthesis support: strengthens the extracellular matrix that contains tumor growth
  • Epigenetic regulation: vitamin C acts as a cofactor for TET enzymes that demethylate DNA
  • Immune stimulation: enhances NK cell and T-lymphocyte activity
  • Reduced chemotherapy toxicity: may protect healthy cells during treatment

What have the main clinical studies reported?

Cameron and Pauling reported 4.2x longer survival in terminal patients in 1976; the NIH confirmed in 2004 that IV delivery reaches 70x higher plasma levels than oral; a 2014 Iowa trial found IV vitamin C safe with chemotherapy.

StudyFindingYear
Cameron & Pauling (PNAS)IV vitamin C + oral: 4.2x longer survival in terminal patients1976
NIH (Padayatty et al.)IV vitamin C achieves 70x higher plasma levels than oral2004
University of Iowa trialIV vitamin C safe and well-tolerated with chemotherapy2014
Cochrane Review (pancreatic)IV vitamin C reduced pain and improved quality of life2015
Frontiers in Oncology meta-analysisIV vitamin C improved survival in multiple cancer types2020

Is IV vitamin C approved as a cancer treatment?

No. The National Cancer Institute notes it has been studied and used safely in clinical settings, but it is not FDA-approved as a cancer treatment. Oral supplements never reach the plasma levels studied.

The National Cancer Institute (USA) states that high-dose IV vitamin C has been studied as a treatment for cancer patients. While it is not currently FDA-approved as a cancer treatment, the NCI acknowledges it has been used safely in clinical settings and is being actively investigated.

💡 Important distinction: Oral vitamin C supplements do NOT achieve the blood levels required for anti-tumor effects. Only intravenous administration can reach pharmacological concentrations. Supplements play a supportive, not therapeutic, role.

Why do some centres pair IV vitamin C with chemo?

Studies suggest it may reduce treatment-related fatigue, protect healthy cells from oxidative damage, enhance the effect of certain agents and improve quality-of-life scores. These remain research findings.

Several oncology centers now use IV vitamin C alongside standard treatments. Studies suggest it may:

  • Reduce chemotherapy-related fatigue
  • Protect against oxidative damage to healthy cells
  • Enhance the cytotoxic effect of certain chemotherapy agents
  • Improve quality of life scores in cancer patients

What can be concluded about vitamin C and cancer?

The evidence is promising but still evolving. Adequate vitamin C status supports antioxidant protection, immunity and quality of life during treatment. Always consult your oncologist before supplementing during cancer care.

The evidence for vitamin C in cancer is promising but evolving. What is clear is that ensuring adequate vitamin C status is beneficial for cancer prevention (through its antioxidant role), immune support, and quality of life during treatment. Always consult your oncologist before any supplementation during cancer treatment.

FAQ

No. IV vitamin C is not approved as a cancer treatment by the FDA or EMA. However, the National Cancer Institute (NCI) acknowledges it has been used safely in clinical settings and is actively being investigated in clinical trials as an adjunct to conventional treatments. Several oncology centres now offer it alongside chemotherapy as supportive care.
Oral vitamin C saturates at approximately 80 µmol/L in plasma regardless of dose, due to intestinal absorption limits. IV vitamin C bypasses this barrier entirely, achieving plasma concentrations of 10,000–20,000 µmol/L — levels 70–100× higher than oral supplementation. Only these pharmacological concentrations generate the pro-oxidant anti-tumour effect seen in clinical studies.
Epidemiological studies show an association between high vitamin C intake and reduced risk of certain cancers (stomach, oesophagus, oral cavity). However, this evidence is observational. Current research supports a preventive role via antioxidant protection of DNA, not a curative role via oral supplementation. The protective effect is most consistent for cancers linked to oxidative damage and inflammation.
No, absolutely not. Vitamin C is being studied as an adjunct to conventional treatments (chemotherapy, radiotherapy), not as a replacement. Stopping or interrupting validated cancer treatment to take vitamin C instead is dangerous and is not supported by any credible scientific evidence. Always consult your oncologist before adding any supplement to your treatment protocol.

Sources: Cameron E., Pauling L. (1976). PNAS. | Levine M et al. (2004). Ann Intern Med. | Chen Q et al. (2005). PNAS. | Ma Y et al. (2014). Journal of Clinical Oncology. | Welsh JL et al. (2013). Cancer Chemotherapy and Pharmacology. | NCI. High-dose Vitamin C (PDQ). | INCa (2020).